Clinical Trial Update: Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation [Phase 3]

View source ↗

Summary

This clinical trial update notes the ongoing Phase 3 study of Revumenib in combination with intensive chemotherapy for newly diagnosed acute myeloid leukemia wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Npm1 Mutation

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Acute Myeloid Leukemias | Phase 3 | Status: RECRUITING